
|Videos|March 29, 2021
Dr. Scott T. Tagawa on radium-223 in prostate cancer
Author(s)Urology Times staff
Advertisement
Scott T. Tagawa, MD, provides expert insight on radium-223 (Xofigo), highlighting pivotal research and next steps with the alpha particle–emitting radioactive therapeutic agent. Tagawa is a professor of Medicine and Urology at Weill Cornell Medicine, and an attending physician at NewYork-Presbyterian/Weill Cornell Medical Center.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












